A six-week antibiotic treatment of endocarditis with spondylodiscitis is not associated with increased risk of relapse: A retrospective cohort study.

Version imprimableSend by emailPDF version
Auteur: 
Castagné, B; Soubrier, M; Prouteau, J; Gadea, E; Vidal, M
Date Publication: 
2020
Mois: 
Novembre
Revue: 
Medecine et maladies infectieuses
ISSN: 
1769-6690
NLM-ID: 
311416
Résumé: 
We compared the relapse rate at 1 year in patients with vertebral osteomyelitis with or without associated endocarditis.We conducted a retrospective cohort study. Inclusion criteria were patients hospitalized in the infectious disease, rheumatology, cardiology, cardiovascular surgery and two internal medicine units for vertebral osteomyelitis (blood culture and/or disco-vertebral biopsy) and compatible imaging, between 2014 and 2017. We compared patients with associated endocarditis (VO-EI group) and without endocarditis (VO group) using logistic regression to determine the factors associated with relapse and EI. The main outcome was the relapse rate at 1 year.Out of the 207 eligible patients, 62 were included (35 in the VO group and 27 in the VO-EI group). Four patients presented with a new VO during follow-up, one (2.86%) patient in VO group and three (11.11%) in VO-EI group (P=0.68). There were more men in the VO-EI group than in the VO group (74.07% vs. 48.57%, P=0.04), valvulopathies (13/27 vs. 8/35, P=0.06), vertebral localization (1.22±0.50 vs. 1.03±0.17, P=0.04) and septic kidney embolism (5/27 vs. 0/35, P=0.01). Control blood cultures were more often positive in the VO-EI group (12/27 vs. 8/35, P=0.04). In 45% of patients, the germ was a staphylococcus, 29% streptococci, 10% enterococci, 10% gram-negative bacillus (GNB). There were more streptococci and enterococci in the VO-EI group than in the VO group (44.44% vs. 17.14% and 18.52% vs. 8.57%, respectively). Antibiotic safety was good and comparable between groups.In a relatively small population, we did not find significantly more relapse in the endocarditis group.
Mots clés auteurs: 
/Antibiotics/Endocarditis/Osteomyelitis
DOI: 
10.1016/j.medmal.2020.10.026
PMID: 
33166612